Sun Pharma Initiates Recall of Multiple Eye Drop Brands Across India Over Contamination
Source: ET Real Estate
Arth Insight · What this means for your wallet
- You might lose the money already spent on the recalled eye drops if Sun Pharma does not offer a refund or replacement plan.
- You will incur immediate out-of-pocket expenses to purchase alternative, safe eye drops from another brand.
- Using contaminated eye drops could lead to infections or other eye problems, potentially increasing your medical bills for doctor consultations and new prescriptions.
Sun Pharmaceutical Industries Ltd. has commenced a product withdrawal for several of its eye drop brands in India, citing contamination concerns. This recall affects a range of commonly used ophthalmic solutions, including Depopred, Brinolar, Brinzotim, Lotepred, Nepalact, and Toba-F products.
- ▸Sun Pharmaceutical Industries has initiated a recall of multiple eye drop brands in India.
- ▸The recall is due to a 'contamination scare' affecting product safety.
- ▸A wide range of eye drops, including brands like Depopred, Brinolar, Lotepred, and Nepalact, are impacted.
- ▸Specific details regarding the contamination type, affected batch numbers, and consumer action steps are not yet publicly available.
- ✓Sun Pharmaceutical Industries has initiated a recall of multiple eye drop brands in India.
- ✓The recall is due to a 'contamination scare' affecting product safety.
- ✓A wide range of eye drops, including brands like Depopred, Brinolar, Lotepred, and Nepalact, are impacted.
- ✓Specific details regarding the contamination type, affected batch numbers, and consumer action steps are not yet publicly available.
Sun Pharmaceutical Industries Ltd., a prominent Indian pharmaceutical company, has initiated a widespread recall of numerous eye drop products across India due to a reported contamination scare. The move underscores the company's commitment to patient safety and adherence to regulatory standards, ensuring that potentially compromised medications are removed from circulation.
The recall specifically targets a comprehensive list of eye drop formulations. Consumers and healthcare providers should be aware of the following products identified for withdrawal:
- Depopred2ML
- Brinolar (BKC FREE)
- Brinzotim Eye Drops 5ML BKC FREE
- Lotepred-5ML
- Lotepred 1% Eye Drops SML
- Lotepred LS 0.2%E/D5ML
- Lotepred T
- Nepalact OD Eye Drops 3ML
- Nepalact-Z
- Toba-F
- Nepalact E/D 5ML
A product recall is a critical action taken by manufacturers when products are found to have defects or pose potential health risks, necessitating their removal from the market. In this instance, the 'contamination scare' indicates that the affected eye drops may contain unwanted substances or microbes that could harm users.
While the specific nature of the contamination (e.g., bacterial, fungal, particulate matter) and the exact batch numbers affected have not been detailed in the immediate report, the recall of such a broad range of products highlights the seriousness of the issue. Eye drops are sterile products designed for direct application to the eye, making any contamination a significant health concern that could lead to infections, irritation, or more severe ocular damage.
As of this report, specific instructions for consumers on what to do if they possess these recalled eye drops, such as return procedures or refund information, have not been publicly detailed. It is advisable for individuals currently using any of the listed eye drops to exercise caution and consult their healthcare provider or pharmacist for guidance.
Sun Pharma's prompt action in initiating this withdrawal is a standard industry practice to uphold product quality and patient safety. Regulatory bodies in India will likely monitor the recall process to ensure its effective implementation and to prevent any further distribution of the affected products.
This report is for informational purposes only and should not be considered medical advice. Always consult a healthcare professional for health concerns.
Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.
Frequently Asked Questions
Which company is recalling eye drops in India?
Sun Pharmaceutical Industries Ltd. is recalling eye drop products in India.
What specific eye drop products are being recalled?
The recalled products include Depopred2ML, Brinolar (BKC FREE), Brinzotim Eye Drops 5ML BKC FREE, Lotepred-5ML, Lotepred 1% Eye Drops SML, Lotepred LS 0.2%E/D5ML, Lotepred T, Nepalact OD Eye Drops 3ML, Nepalact-Z, Toba-F, and Nepalact E/D 5ML.
Why are these eye drops being recalled?
The eye drops are being recalled due to a 'contamination scare,' indicating potential safety issues with the products.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about real-estate
Aayush Wellness Launches Calcium & Vitamin D Tablets, Enters ₹1.35 Lakh Crore Bone Health Market
Aayush Wellness Limited has launched new calcium and vitamin D tablets, marking its entry into India's significant bone and joint health segment. This expansion reflects the growing consumer demand for preventive healthcare and nutritional supplements designed to support musculoskeletal health.
NITI Aayog Eyes Policy Reforms to Boost India's Medical Device Manufacturing
NITI Aayog is actively exploring new policy measures to enhance India's domestic manufacturing capabilities for medical and dental devices. The initiative addresses significant hurdles like complex regulations and cost disadvantages faced by local producers. The goal is to strengthen the 'Make in India' drive within the crucial healthcare sector.
Health Ministry Ordered to Probe Coronary Stent Safety Concerns by Cabinet Secretariat
The Cabinet Secretariat has directed the Union Health Ministry to investigate safety concerns surrounding coronary stents. This action follows concerns raised by Rajya Sabha member Ajeet Madhavrao Gopchade, highlighting issues with models withdrawn in Sri Lanka and calling for a stronger regulatory framework in India.
Related Stories
Aayush Wellness Launches Calcium & Vitamin D Tablets, Enters ₹1.35 Lakh Crore Bone Health Market
Aayush Wellness Limited has launched new calcium and vitamin D tablets, marking its entry into India's significant bone and joint health segment. This expansion reflects the growing consumer demand for preventive healthcare and nutritional supplements designed to support musculoskeletal health.
NITI Aayog Eyes Policy Reforms to Boost India's Medical Device Manufacturing
NITI Aayog is actively exploring new policy measures to enhance India's domestic manufacturing capabilities for medical and dental devices. The initiative addresses significant hurdles like complex regulations and cost disadvantages faced by local producers. The goal is to strengthen the 'Make in India' drive within the crucial healthcare sector.
Health Ministry Ordered to Probe Coronary Stent Safety Concerns by Cabinet Secretariat
The Cabinet Secretariat has directed the Union Health Ministry to investigate safety concerns surrounding coronary stents. This action follows concerns raised by Rajya Sabha member Ajeet Madhavrao Gopchade, highlighting issues with models withdrawn in Sri Lanka and calling for a stronger regulatory framework in India.
Biocon to Launch Cancer Drug Pebrilzo in EU/UK by 2027, US by 2028 After Settlement
Biocon has resolved all legal disputes with Genentech regarding its cancer drug Pebrilzo through a global settlement and license agreement. This crucial development paves the way for Biocon to launch Pebrilzo in the European Union and the United Kingdom by early 2027, followed by the United States in the third quarter of 2028.